Mechanism of Action and Structural Features
Nebivolol has a unique chemical structure. It is a racemic mixture composed of two enantiomers, each determining a specific part of its pharmacodynamics.
- The d-isomer is a highly selective $\beta_1$-adrenergic receptor blocker. Its affinity for myocardial $\beta_1$-receptors exceeds its affinity for $\beta_2$-receptors by 300 times, making it the leader in cardioselectivity among analogues.
- The L-isomer is responsible for a fundamentally different effect: it actively stimulates the production of endothelial nitric oxide (NO).
In addition, the drug increases prostacyclin synthesis. The combination of these effects results in pronounced vasodilation, which, together with classic adrenergic blockade, provides reliable blood pressure reduction.
Pleiotropic Effects and Metabolic Profile
Pleiotropic effects distinguish this drug from older representatives of the class, such as propranolol. First and foremost, this concerns its metabolic profile, making it well-suited for patients with concurrent endocrine disorders.
- Carbohydrate metabolism: the drug significantly reduces insulin resistance and improves glucose utilization by peripheral tissues, which is critical in type 2 diabetes mellitus.
- Lipid metabolism: therapy is associated with favorable changes — triglyceride concentrations decrease, while high-density lipoprotein (HDL) cholesterol levels increase.
Alongside metabolic benefits, the drug exhibits pronounced antioxidant activity and inhibits platelet aggregation and adhesion, providing an antithrombotic effect.
Clinical Application and Safety Profile
In clinical practice, the drug is prescribed for the treatment of arterial hypertension and stable angina pectoris. In angina, an additional advantage is its ability to dilate coronary vessels specifically via the NO-releasing mechanism. It is also used in the management of mild to moderate chronic heart failure (CHF).
A convenient once-daily dosing regimen improves patient adherence. Due to its high selectivity, adverse events typical of non-selective blockers (e.g., bronchospasm) are minimized.
However, clinicians must keep in mind that cardioselectivity is a dose-dependent phenomenon. Selectivity decreases when the standard dose is increased from 5 mg to 10 mg daily, as well as in individuals with specific metabolic profiles.
Metabolic Genetics (CYP2D6)
The drug's pharmacokinetics are heavily dependent on the patient's genetic profile, specifically the polymorphism of the hepatic cytochrome CYP2D6 isoenzyme.
- In extensive metabolizers (high enzyme activity), the drug undergoes intensive first-pass hepatic metabolism. Consequently, its bioavailability is only about 12%, and the half-life ($T_{1/2}$) is approximately 10 hours.
- In poor metabolizers, the picture is different: enzyme activity is low, resulting in a bioavailability approaching nearly 96% and a prolonged half-life ($T_{1/2}$) of 30–50 hours.
In poor metabolizers, active substance concentrations in the blood are significantly higher, predictably leading to a marked decrease in cardioselectivity. Due to pronounced interindividual variability, it is crucial to account for concurrent medications that affect CYP2D6 activity.